Growth Metrics

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (QoQ) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -404.41%
Dec 31, 2025 -147.73%
Sep 30, 2025 716.74%
Jun 30, 2025 -83.62%
Mar 31, 2025 2,825.25%
Dec 31, 2024 -108.81%
Sep 30, 2024 -68.14%
Jun 30, 2024 -53.16%
Mar 31, 2024 107.46%
Dec 31, 2023 -2,640.39%
Sep 30, 2023 114.57%
Jun 30, 2023 -17.42%
Mar 31, 2023 107.50%
Dec 31, 2022 -512.41%
Sep 30, 2022 -109.46%
Jun 30, 2022 455.20%
Mar 31, 2022 28.43%
Dec 31, 2021 19.53%
Sep 30, 2021 -26.65%
Jun 30, 2021 11.19%
Mar 31, 2021 -18.68%
Dec 31, 2020 -17.93%
Sep 30, 2020 7.04%
Jun 30, 2020 -325.56%
Mar 31, 2020 70.22%
Dec 31, 2019 -7.11%
Sep 30, 2019 7.79%
Jun 30, 2019 8.64%
Mar 31, 2019 -39.18%
Dec 31, 2018 -40.85%
Sep 30, 2018 -18.70%
Jun 30, 2018 -28.56%
Mar 31, 2018 12.36%
Dec 31, 2017 0.69%
Sep 30, 2017 41.06%
Jun 30, 2017 -137.51%
Mar 31, 2017 -10.35%
Dec 31, 2016 21.40%
Sep 30, 2016 1.28%
Jun 30, 2016 -34.55%
Mar 31, 2016 44.80%
Dec 31, 2015 -80.15%
Sep 30, 2015 16.70%
Jun 30, 2015 35.78%
Mar 31, 2015 -48.20%
Dec 31, 2014 6.26%
Sep 30, 2014 40.27%
Jun 30, 2014 45.76%
Mar 31, 2014 -12.28%
Dec 31, 2013 -3.54%
Sep 30, 2013 -4.29%
Jun 30, 2013 -53.37%
Mar 31, 2013 49.67%
Dec 31, 2012 -103.40%
Sep 30, 2012 -154.37%
Jun 30, 2012 541.52%
Mar 31, 2012 123.04%
Dec 31, 2011 -8.29%
Sep 30, 2011 -301.15%
Jun 30, 2011 -117.93%
Mar 31, 2011 681.65%
Dec 31, 2010 -187.05%
Sep 30, 2010 -34.27%